SCHEMBL19257091

SCHEMBL19257091

CCCC(C)(C)c1ccc2cnccc2c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 5/20 0.47
PRKCH P24723 3/20 0.35
PRKCE Q02156 3/20 0.35
PRKCQ Q04759 3/20 0.35
PRKCD Q05655 3/20 0.35
PRKCB P05771 2/20 0.34
PRKCA P17252 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2D6 P10635 2/20 0.34
PRKD3 O94806 1/20 0.34
PRKCG P05129 1/20 0.34
GLA P06280 1/20 0.34
NFKB1 P19838 1/20 0.34
PRKCI P41743 1/20 0.34
PRKCZ Q05513 1/20 0.34
PRKD1 Q15139 1/20 0.34
LMNA P02545 2/20 0.33
LATS1 O95835 2/20 0.33
PMP22 Q01453 1/20 0.33
LATS2 Q9NRM7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19256234 0.84 IMPDH2 (0.36) IMPDH2PRKCHPRKCEPRKCQPRKCD
SCHEMBL9880929 0.81 IMPDH2 (0.56) IMPDH2PRKCHPRKCEPRKCQPRKCD
SCHEMBL25541010 0.80 SSTR4 (0.46) PRKCHPRKCEPRKCQPRKCDPRKCB
SCHEMBL22792452 0.79 CLK1 (0.34) HTR2AHTR2CHTR2B
SCHEMBL22140358 0.74 GAA (0.34) PRKCHPRKCEPRKCQPRKCDLATS1
SCHEMBL22794684 0.72 LMNA (0.46) PRKCHPRKCEPRKCQPRKCDPRKCB
SCHEMBL9883128 0.71 IMPDH2 (0.56) IMPDH2PRKCHPRKCEPRKCQPRKCD
SCHEMBL22043055 0.69 CYP2E1 (0.36) CYP3A4CYP2D6LMNACYP1A2CYP2C9
SCHEMBL22043381 0.69 PRKCH (0.33) PRKCHPRKCEPRKCQPRKCDCYP3A4
SCHEMBL19185523 0.69 TDP1 (0.34) PRKCHPRKCEPRKCQPRKCDCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951059-B2 Dual mechanism inhibitors for the treatment of disease AERIE PHARMACEUTICALS, INC. (US) 2018-04-24 US disclosed
US-20170233381-A1 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE ALCON INC. (CH) 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233381-A1 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE RHOA, SLC6A2, ROCK2 IMPDH2 236/4885PRKCH 129/4885PRKCE 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.